argenx NV ADR (ARGX)vsCrispr Therapeutics AG (CRSP)
ARGX
argenx NV ADR
$897.85
+0.68%
HEALTHCARE · Cap: $54.94B
CRSP
Crispr Therapeutics AG
$54.26
+0.28%
HEALTHCARE · Cap: $4.76B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 44072% more annual revenue ($5.92B vs $13.39M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CRSP
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$897.85
$1669.09 discount
Margin of Safety
+37.5%
Fair Value
$77.26
Current Price
$54.26
$23.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 1041.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 166.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -31.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CRSP
The strongest argument for CRSP centers on Revenue Growth. Revenue growth of 1041.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CRSP
The primary concerns for CRSP are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CRSP is a hypergrowth play — different risk/reward profiles.
CRSP carries more volatility with a beta of 1.76 — expect wider price swings.
CRSP is growing revenue faster at 1041.0% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 34/100), backed by strong 31.7% margins and 52.1% revenue growth. CRSP offers better value entry with a 37.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Crispr Therapeutics AG
HEALTHCARE · BIOTECHNOLOGY · USA
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?